Adjunct therapies to bacterial sepsis in the neonate

Recent steps to prevent neonatal sepsis due to group B Streptococcal infection have lowered the attack rate from this organism, but may not have lowered overall sepsis rates. Mortality from sepsis stills remains between 20 and 40% and is probably so high due to the immunological immaturity of the newborn. Although antibiotics remain the mainstay for treatment, adjunctive therapies aimed at improving the immunological integrity of the neonatal patient have a role in treatment and may improve outcomes. We discuss several adjunctive therapies, along with the physiologic rationale for their use, and discuss an approach for their inclusion in therapy for neonatal sepsis.